Q-omics provides the consensus-scored PRELID1P7 profile across patient tissues and cancer cell-line models. PRELID1P7 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PRELID1P7 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, PRELID1P7 RNA expression shows 6,689 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, THCA, and STAD as cancer lineages where PRELID1P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRELID1P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRELID1P7 survival associations across molecular data types. PRELID1P7 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRELID1P7 RNA expression–survival associations across cancer types. High PRELID1P7 expression shows unfavorable associations in LIHC, ESCA and TGCT, but favorable associations in UVM, SKCM and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PRELID1P7 RNA expression.
This table summarizes PRELID1P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PRELID1P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRELID1P7 shows lower tumor expression in KIRC and higher tumor expression in THCA and KICH. The THCA box plot shows higher PRELID1P7 RNA expression in tumor versus normal tissue (log2 FC = +0.865, t-test p < 0.001).
This table shows molecular features associated with PRELID1P7 in patient tissues and cancer cell lines. In patient samples, PRELID1P7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
